WO2010146595A3 - Novel polymorphs of flibanserin hydrochloride - Google Patents
Novel polymorphs of flibanserin hydrochloride Download PDFInfo
- Publication number
- WO2010146595A3 WO2010146595A3 PCT/IN2009/000347 IN2009000347W WO2010146595A3 WO 2010146595 A3 WO2010146595 A3 WO 2010146595A3 IN 2009000347 W IN2009000347 W IN 2009000347W WO 2010146595 A3 WO2010146595 A3 WO 2010146595A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hemihydrate
- flibanserin hydrochloride
- novel polymorphs
- anhydrous
- flibanserin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
The present invention provides novel crystalline anhydrous form II, hemihydrate form III, anhydrous form IV, anhydrous form V, anhydrous form VI, hemihydrate form VII, hemihydrate form VIII, hemihydrate form IX and amorphous form of flibanserin hydrochloride, processes for its preparation and to pharmaceutical compositions containing them.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IN2009/000347 WO2010146595A2 (en) | 2009-06-16 | 2009-06-16 | Novel polymorphs of flibanserin hydrochloride |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IN2009/000347 WO2010146595A2 (en) | 2009-06-16 | 2009-06-16 | Novel polymorphs of flibanserin hydrochloride |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010146595A2 WO2010146595A2 (en) | 2010-12-23 |
WO2010146595A3 true WO2010146595A3 (en) | 2013-02-07 |
Family
ID=43356830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2009/000347 WO2010146595A2 (en) | 2009-06-16 | 2009-06-16 | Novel polymorphs of flibanserin hydrochloride |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010146595A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017055935A1 (en) * | 2015-09-30 | 2017-04-06 | Symed Labs Limited | Amorphous co-precipitates of flibanserin |
WO2017076356A1 (en) * | 2015-11-05 | 2017-05-11 | 苏州晶云药物科技有限公司 | Novel crystal form of flibaserin, and preparation method therefor |
CN106866546A (en) * | 2015-12-10 | 2017-06-20 | 常州爱诺新睿医药技术有限公司 | Solid dispersions of flibanserin or its pharmaceutically acceptable salt and pharmaceutic adjuvant and preparation method thereof |
WO2017128932A1 (en) * | 2016-01-31 | 2017-08-03 | 孟晓明 | Novel polymorph of flibanserin and preparation method thereof and use of same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5576318A (en) * | 1991-07-30 | 1996-11-19 | Boehringer Ingelheim Italia S.P.A. | Benzimidazolone derivatives |
WO2003013539A1 (en) * | 2001-08-10 | 2003-02-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neuroprotective drug |
WO2006119958A2 (en) * | 2005-05-13 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Use of flibanserin in the treatment of chronic pain |
-
2009
- 2009-06-16 WO PCT/IN2009/000347 patent/WO2010146595A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5576318A (en) * | 1991-07-30 | 1996-11-19 | Boehringer Ingelheim Italia S.P.A. | Benzimidazolone derivatives |
WO2003013539A1 (en) * | 2001-08-10 | 2003-02-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neuroprotective drug |
WO2006119958A2 (en) * | 2005-05-13 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Use of flibanserin in the treatment of chronic pain |
Also Published As
Publication number | Publication date |
---|---|
WO2010146595A2 (en) | 2010-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010092090A3 (en) | Novel salts of sitagliptin | |
WO2010139981A3 (en) | Processes for preparing crystalline forms of dasatinib | |
WO2011098582A3 (en) | Novel crystalline forms of ivabradine hydrochloride | |
WO2009104021A3 (en) | Novel polymorphs and processes for their preparation | |
EA201171151A1 (en) | CRYSTALLINE TRIPEPTIDE EPOXYKETON-PROTEASE INHIBITORS | |
HK1170241A1 (en) | Process for the preparation of compounds useful as inhibitors of sglt2 sglt2 | |
WO2012070062A3 (en) | Novel polymorph of nilotinib hydrochloride | |
WO2010139979A3 (en) | Processes for preparing crystalline forms of dasatinib | |
WO2012015681A3 (en) | Drug-ligand conjugates, synthesis thereof, and intermediates thereto | |
WO2012015999A3 (en) | Process for the preparation of imatinib mesylate | |
WO2010049449A3 (en) | Novel salts of sunitinib | |
EP2216333A3 (en) | Crystalline forms of Dexlansoprazole | |
WO2010008735A3 (en) | Solid states of o-desmethylvenlaf axine salts | |
WO2012131707A3 (en) | Crystalline form of bortezomib, preparation method and pharmaceutical composition there f | |
WO2010129636A3 (en) | Lenalidomide polymorph | |
MY161749A (en) | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | |
WO2010079045A3 (en) | Crystalline salt forms of flibanserine | |
IN2012DN01292A (en) | ||
WO2010006904A3 (en) | Crystalline forms of rabeprazole sodium | |
WO2010131035A8 (en) | Novel crystalline polymorph of sitagliptin dihydrogen phosphate | |
WO2010146595A3 (en) | Novel polymorphs of flibanserin hydrochloride | |
WO2010027848A3 (en) | Forms of lapatinib compounds and processes for the preparation thereof | |
AP2012006280A0 (en) | Synthesis process, and crystalline form of 4-ä3-ÄCis-hexahydrocyclopentaÄCÜpyrrol-2(1H)-YLÜpropoxyübenzamide hydrochloride and pharmaceutical compositions containing it. | |
WO2011058524A3 (en) | Crystalline forms of bosentan salts and processes for their preparation | |
WO2010061220A3 (en) | Novel processes and pure polymorphs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09846109 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09846109 Country of ref document: EP Kind code of ref document: A2 |